SciELO - Scientific Electronic Library Online

vol.9 número3Persistência da veia ciáticaEstudos clínicos de não-inferioridade: fundamentos e controvérsias índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados


Jornal Vascular Brasileiro

versão impressa ISSN 1677-5449


YOSHIDA, Winston Bonetti. Studies on biosimilar medications. J. vasc. bras. [online]. 2010, vol.9, n.3, pp.141-144. ISSN 1677-5449.

In Brazil, the registration of new drugs is carried out only when the regulatory agency (Anvisa, acronym in Portuguese) is fully satisfied with the evidence of their quality, efficacy and safety, presented by a pharmaceutical industry that strive for this registration. With the patent expiration, pharmaceutical companies are attracted to produce biological medicines called biosimilar or biogenerics or simply generics, whose approval may result in reduced treatment costs. But it is necessary that the biosimilar be, at least, equally effective and safe and without contaminants in relation to the original. Recent consensus guidelines aim to establish criteria for efficacy and safety of these medicines. Preclinical studies in vitro and in vivo, the origin of raw materials and clinical studies phase I, II and III are recommended for biosimilar medicine registration in the international market. Low molecular weight heparins are found in this situation. In this review we specifically addressed this type of medicine, which could serve as a benchmark for other biosimilar medicines.

Palavras-chave : Heparin; heparin, low-molecular-weight; drugs, generic; practice guidelines as topic; therapeutic equivalence.

        · resumo em Português     · texto em Português | Inglês     · Português ( pdf ) | Inglês ( pdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons